{
  "abstract": "Developing a prophylactic vaccine protecting from chronic hepatitis C virus (HCV) infection remains a high priority in efforts to end this worldwide pandemic.1 There is a broad consensus that a successful prophylactic vaccine should induce both humoral and T-cell responses for the highest efficacy in preventing chronic infection.2 However, detailed characteristics of T-cell and antibody responses that a vaccine must elicit for effective protection await full definition. It also remains open whether sterilising immunity against different HCV strains is a realistic goal. Protection from persistence appears more feasible, based on observations that, although spontaneous clearance of acute HCV infection is often followed by reinfections in high-risk populations, the likelihood of repeated HCV clearance is high.3",
  "authors": [
    {
      "affiliations": [
        "Université Claude-Bernard Lyon 1, INSERM, UMR 1350 PaThLiv, Lyon, France",
        "The Lyon Hepatology Institute, IHU EVEREST, Lyon, France"
      ],
      "name": "Birke Bartosch"
    },
    {
      "affiliations": [
        "Division of Gastroenterology, Massachusetts General Hospital, Boston, Massachusetts, USA",
        "Harvard Medical School, Boston, Massachusetts, USA",
        "Broad Institute, Cambridge, Massachusetts, USA"
      ],
      "name": "Georg M Lauer"
    }
  ],
  "title": "Catch me if you can! Is there protection from HCV (re)infection?",
  "uid": "968579d8-4945-5765-9bd3-abdd978b65c5"
}